| 引用本文: | 赵诗哲,徐佳宝,毛金校.SHCBP1:乳腺癌治疗候选靶点和潜在预后标志物[J].生物信息学,2020,18(1):45-55. |
| ZHAO Shizhe,XU Jiabao,MAO Jinxiao.SHCBP1: A breast cancer treatment target candidate and potential prognostic marker[J].Chinese Journal of Bioinformatics,2020,18(1):45-55. |
|
| 摘要: |
| 探讨SHCBP1在乳腺癌及其不同亚型中的表达特征和预后价值。利用Oncomine, bc-GenExMiner v4.2, Kaplan-Meier plotter, GSE41994及STRING数据库分析乳腺癌病人SHCBP1的mRNA表达水平及其与乳腺癌患者生存率的相关性等。结果:(1)乳腺癌组织中SHCBP1的mRNA水平明显高于正常组织样本,但不同分子亚型的乳腺癌患者中SHCBP1的表达水平不同；(2) SHCBP1表达升高可导致Luminal A亚型更短的无转移生存期(Distant metastasis-free survival,DMFS)和无病生存期(Disease-free survival, DFS)；(3)在雌激素受体阳性(ER+)、孕酮受体阳性(PR+)亚型、仅接受辅助化疗、仅接受辅助化疗的ER(+)与接受包括或排除内分泌治疗乳腺癌患者中,SHCBP1表达升高则无复发生存率(Relapse-free survival,RFS)显著缩短；(4) SHCBP1和CDC45 mRNA表达水平之间呈正相关,并可能与KIF23等10种蛋白相互作用。结论:SHCBP1是一种很有前景的乳腺癌预后指标和潜在的治疗靶点。 |
| 关键词: SHCBP1 乳腺癌 表达水平 预后价值 |
| DOI：10.12113/201909004 |
| 分类号:R737.9 |
| 文献标识码:A |
| 基金项目: |
|
| SHCBP1: A breast cancer treatment target candidate and potential prognostic marker |
|
ZHAO Shizhe2, XU Jiabao2, MAO Jinxiao1
|
|
(1. Department of Pharmacy, Childrens Hospital of Chongqing Medical University; Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Chongqing Key Laboratory of Pediatrics, Chongqing 400010, China; 2. Department of Pathology, Basic Medical College, Henan University, Kaifeng 475004, Henan, China)
|
| Abstract: |
| To investigate the expression characteristics and prognostic value of SHCBP1in breast cancer and its relevant subtypes, the Oncomine, bc-GenExMiner v4.2, Kaplan-Meier plotter, GSE41994, and STRING databases were used to analyze the mRNA expression level of SHCBP1in breast cancer patients and its correlation with their survival rate. Results show that: (1) The mRNA level of SHCBP1in breast cancer tissues was significantly higher than that of normal tissue samples, but the expression level of SHCBP1in breast cancer patients with different molecular subtypes was different; (2) Increased expression of SHCBP1might lead to shorter distant metastasis-free survival (DMFS) and disease-free survival (DFS) of Luminal A subtype; (3) In patients with ER(+), PR(+) subtype, chemo-adjuvant only, ER(+) with chemo-adjuvant therapy, endocrine therapy-include, and endocrine therapy-exclude breast cancer, elevated SHCBP1expression significantly correlated with shorten relapse-free survival rate (RFS); (4) SHCBP1and CDC45 mRNA expression levels were positively correlated and SHCBP1might interact with 10 proteins such as KIF23. Therefore, SHCBP1may be a promising prognostic indicator and therapeutic target for breast cancer. |
| Key words: SHCBP1 Breast cancer Expression level Prognostic value. |
